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ABSTRACT 
Background: Toxoplasmosis is a common cause of foodborne, gastrointestinal and congenital syndrome with 
particularly severe or unknown health consequences. There is no safe and effective preventive or therapeutic 
modality against congenital toxoplasmosis or to eliminate the persistent chronic infection. Hypothesis: Diclazuril 
to be safe in pregnancy and effective against gastrointestinal toxoplasmosis. Methods: CD1 programmed preg-
nant mice were divided into groups and administered a diet containing diclazuril, or sham control. Treatments 
were initiated on Day 5 of pregnancy and continued until Day 16 when dams were euthanatized. On Day 8 of 
pregnancy dams were infected intraperitoneally with escalating doses of tachyzoites (0, 100, 300, 600) from Type 
II strain. Dams were monitored daily for distress, pain, and abortion and samples collected at the end of the ex-
periments. Results: Infected dams developed moderate to severe Toxoplasma related complications in tachyzoites 
dose dependent manner. Animals became anemic and showed hydrothorax, and ascities. Diclazuril effectively 
protected dams from ascities and anemia (p < 0.05). Infected dams showed splenomegaly, with massive infiltra-
tion of epithelioid cells compared with the protective effect of diclazuril in treated animals. Infected dams exhi-
bited severe hepatitis (score 0 to 4 scale = 3.5 ± 0.01) with influx of inflammatory and plasma cells, dysplastic 
hepatocytes, multinucleated giant cell transformation and hepatic cells necrosis. Diclazuril treatment signifi-
cantly protected dams from hepatitis, also in tachyzoites dose (100, 300, 600) dependent manner (respectively 
infected-treated versus infected controls, p < 0.001, p < 0.01 and p < 0.05). Colonic tissues were significantly 
shortened in length, with infiltration of lymphocytes, and macrophages and microabscess formations in the cryp-
tic structures, with significant improvement in diclazuril treated animals. Additionally, the number of fetuses, 
fetal length and fetal weight were preserved in diclazuril treated dams. Conclusions: This is the first report de-
scribing of diclazuril safety in pregnancy as well as efficacy against mild to moderate hepato-gastrointestinal 
syndrome in dams and fetal toxoplasmosis (Special issue, “Treatment of Liver Diseases”). 
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1. Introduction 
Toxoplasma gondii is an important source of foodborne 
hospitalization and congenital disorders that infects hu-
mans and animals. Toxoplasmosis manifests with gastro- 
intestinal disorders to severe cerebral, ocular and fetal 
complications. Toxoplasmosis in immunocompetent peo- 
ple is typically symptomless or may appear as flu like 
syndrome. However, it can lead to severe complications 
and death in immunocompromised hosts, fetus and neo-
nates [1]. It is predicted that 1,500,000 cases of toxop-
lasmosis occur in the USA each year, and about 15% of 
these cases reveal clinical symptoms [2].  
Latent toxoplasmosis can become reactivated mainly 
in AIDS and in immunocompromised patients and during *Corresponding author. 
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pregnancy. Congenital toxoplasmosis occurs in man and 
animals [3] by transplacental transmission of organisms 
during maternal infection. Maternal-fetal transmission 
was first reported in an infant in New York in 1939 [4], 
and its consequences have long been recognized [5]. Con- 
genital toxoplasmosis manifests with spontaneous abor-
tion, intrauterine fetal death or severe congenital defects, 
including encephalitis [6].  
There is currently no safe and effective (FDA ap-
proved) therapy against congenital toxoplasmosis to pre-
vent or eliminate fetal complications and persistent chro- 
nic Toxoplasma infections. Current therapies include spi- 
ramycin alone or associated with pyrimethamine-sulfa- 
doxine, to prevent transfer of Toxoplasma from the ac-
tively infected mother to the fetus and to treat the infec- 
ted fetus. However, this approach is not always effective 
and is associated with unwanted side effects [7-10]. Ato- 
vaquone (hydroxy-1,4-naphthoquinone) which is an FDA 
approved treatment for toxoplasmosis yet is not in use for 
congenital toxoplasmosis [7]. Recently, we have reported 
that atovaquone protects dams and their fetuses against 
some infectious and inflammatory aspects of toxoplas-
mosis [11].  
Diclazuril [4-chlorophenyl [2,6-dichloro-4-(4,5-dihy- 
dro-3H-3,5-dioxo-1,2,4-triazin-2-yl)pheny l acetonitrile] 
is widely used in prevention and treatment of poultry and 
livestock coccidiosis and Equine Protozoal Myeloence- 
phalitis (EPM) in horses [12]. Diclazuril is a safe com-
pound [13] with no known side effects at therapeutic 
dose levels. However, diclazuril has not been tested or 
used in pregnancy.  
Diclazuril acts by specifically targeting a chloroplast 
derived chlorophyll a-D1 complex present in Apicom-
plexan and not represented in mammalian systems [14]. 
As such, diclazuril and its related substances have the 
potential for high anti-Apicomplexan therapeutic efficacy 
and minimal mammalian toxicity. Diclazuril has not been 
tested in pregnancy in general or congenital toxoplasmosis.  
The objectives of this study were diclazuril to be safe 
in pregnancy and effective treatment against the maternal 
gastrointestinal syndrome as well as progression of con-
genital toxoplasmosis in our murine pregnancy model of 
toxoplasmosis.  
2. Materials and Methods 
2.1. Ethics 
This research was conducted according to the guidelines 
and approved by the Institutional Biosaftey Committee 
(IBC) and the IACUC at University of Kentucky Medical 
Center. 
2.2. Toxoplasma gondii Propagation 
Toxoplasma Type II isolates including ME-49 strain are 
predominant in human congenital toxoplasmosis [15]. 
For this investigation, Toxoplasma organisms from PTG 
strain (ME-49, ATCC50841™) were originally cloned, 
and propagated by Dr. Daniel Howe from Maxwell H. 
Gluck Equine Center at the University of Kentucky [11, 
16]. Briefly, tachyzoites were cultured by serial passage 
in bovine turbinate cells and maintained in minimum 
essential Medium (MEM-RS, HyClone Labs, Inc.) sup-
plemented with 4% fetal clone III (HyClone, Labs, Inc.), 
Penicillin/Streptomycin/Fungizone (BioWhittaker, Inc.), 
and non-essential amino acids solution (HyClone, Labs, 
Inc.). Upon disruption of the host cell monolayer, extra-
cellular tachyzoites were harvested and purified from 
host cell debris by filtration through 3.0 µm membranes. 
Tachyzoites were enumerated in a hemocytometer and 
suspended in phosphate buffer saline (PBS) to the appro-
priate concentrations for inoculation. All inoculations 
were administered intraperitoneally (i.p.) in 100 µl vo-
lume into dams within 1h of harvest to ensure viability.  
2.3. Murine Fetal Toxoplasmosis Model 
Murine play an important role in propagation and trans-
mission of Toxoplasma and are commonly used in stud-
ying toxoplasmosis. In addition, CD1 mice are hardy 
animals with relatively large number of pups and rou-
tinely used in pregnancy investigations (11, 17). There-
fore, sixty Day 1 programmed pregnant (9 weeks old) 
CD1 dams were purchased from Charles River Lab Inc. 
Wilmington, MA). Dams were housed individually in 
micro-isolator cages in a pathogen free environment and 
maintained at 22˚C with a 12:12-hr light: dark cycle at 
the Maxwell H. Gluck Equine Research Center Labora-
tory Animal Facility. Dams were fed irradiated rodent 
chow and sterilized drinking water ad libitum. After ac-
climation, (Day 8 pregnancy) dams were weighed and 
ear-punched for appropriate identification. They were 
assigned into 6 - 10 animals per group, and injected i.p. 
with 100 µl PBS containing 0, 100, 300, or 600 tachy-
zoites using 0.5 ml insulin syringes. Control dams re-
ceived 100 µl sham injection with PBS alone. Animals 
were monitored 3 times daily for physical appearance, 
distress, pain, diarrhea and vaginal discharge to detect 
early delivery or abortion [11,17]. The experiment was 
terminated on gestation Day 16 before possible early or 
premature birth to study the feto-maternal aspects of the 
disease.  
Animals were euthanatized using CO2 inhalation. 
Their chests were immediately opened and blood from 
heart collected in microtainer (BD Biosource, Rockville, 
MD) for hematocrit evaluation. Sera were separated and 
stored frozen at −80˚C. The splenic weight and length 
were recorded. Heart, liver and uterus were excised and 
weighed. Colonic contents were removed and colonic 
length and weight recorded then flash frozen in liquid 
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nitrogen and stored at −80˚C for future studies. Live fe-
tuses were removed from uteri, counted, weighed and 
their lengths measured using a digital caliper.  
2.4. Diclazuril Treatment 
Diclazuril is currently used in coccidiosis in poultry and 
EPM in equines but has not been tested in pregnancy or 
congenital toxoplasmosis. In order to study safety and 
efficacy of 65 mg/kg and 120 mg/kg diclazuril against 
fetal and maternal toxoplasmosis complications, animals 
were divided into groups of 6 - 8 animals. Dams received 
treatment regimens incorporated into daily diet as indi-
cated in our previous publication [11]. Control groups 
received sham treatment (inert talcum powder). Treat-
ment was initiated on Day 5 of pregnancy and continued 
until Day 16 when dams were euthanatized. Pregnant 
animals’ were monitored daily for food consumption and 
changes in their appearance, food consumption or weight 
loss/gain. On Day 8 of pregnancy dams on treatment or 
sham control arms were further divided into 4 subgroups 
of 6 - 8 animals each and were injected each with 0 (PBS), 
100, 300, or 600 tachyzoites and the treatments continued. 
Three different tachyzoites infective doses were chosen 
based on our previous study [11] to develop a mild (100), 
moderate (300) and severe (600) toxoplasmosis to best 
represent the common disease process in infected pa-
tients in general. This range also enabled us to perform 
the investigation in accordance with IACUC regulation 
to prevent excess animals use and unnecessary demise.  
2.5. Histopathological Examination  
2.5.1. Hepatic Tissues 
A portion of the right lobe from liver tissues was placed 
in cassettes and fixed with 10% neutral formalin. The 
specimens were dehydrated and embedded in paraffin, 
and tissue sections of 5 µm were stained by Hematoxylin 
Eosin (H & E) [11,18]. Each slide was evaluated under 
Ziess light microscopy. Hepatic lesions were graded on a 
scale of 0 to 4+, based on degeneration, inflammation, 
and necrosis as follows: 
Grade 0: No detectable lesions, no degeneration, no in-
filtration of inflammatory cells, normal tissue appearance. 
Grade 1: Focal infiltration of inflammatory cells in the 
hepatic structure, and random hepatocytes degeneration.  
Grade 2: Mild multi-focal infiltration of inflammatory 
cells, and hepatocytes degeneration.  
Grade 3: Moderate multi-focal infiltration of inflam-
matory cells, and hepatocytes degeneration.  
Grade 4: Severe diffuse inflammation, and necrosis. 
2.5.2. Colonic Tissue and H & E Staining 
Colonic tissues were flushed with PBS (pH 7.2) and a 
portion from proximal and distal colonic tissue was fixed 
in 10% neutral formalin for histological examinations. 
The remainder was snap-frozen in liquid nitrogen and 
stored at −80˚C. The formalin fixed sections were 
processed and stained with hematoxylin and eosin (H & 
E), and slides evaluated by Ziess light microscopy. Se-
verity of colitis was assessed with a histological semi- 
quantitative grading score and performed in a blinded 
fashion. The scores were based on histopathological fea-
tures with a numeric value (0-normal to 4-severe) as-
signed according to the tissue involvement [19,20] that 
corresponded to either of the following criteria:  
Grade 0: No detectable lesions, no inflammatory cells, 
normal mucosal appearance. 
Grade 1: Focal inflammatory infiltrate in the mucosa.  
Grade 2: Mild multi-focal inflammation with moderate 
expansion of the mucosa. 
Grade 3: Moderate multi-focal inflammation with mo- 
derate expansion of the mucosa. 
Grade 4: Severe diffuse inflammation with crypt epi-
thelium disruption and ulceration.  
2.5.3. Giemsa Staining 
Giemsa is a delicate polychromatic stain that reveals a 
fine nuclear detail of Toxoplasma organisms. Giemsa 
stain contains Methylene Blue Azure Basic dyes com-
bined with Eosin Acidic dyes. The deparaffinized slide 
sections were stained with the polychromatic Giemsa (40 
drops/50 ml distilled water) to stain nuclei of the Toxop-
lasma organisms and to permit differentiation among the 
cells. Then, the slides were depreciated in 1% Glacial 
Acetic Acid, dehydrated in alcohol and xylene series and 
mounted in synthetic resin on slides. 
2.5.4. Immunohistochemical Staining (IHC) 
Anti-Toxoplasma antibody and IHC procedure were 
kindly provided by Dr David S. Lindsay at at Department 
of Biomedical Science and Pathology, Virginia Tech. 
Briefly, paraffin-embedded sections were cut, deparaffi-
nized with xylene, rehydrated in alcohol baths, washed in 
PBS with 0.1% BSA, The endogenous peroxidase activ-
ity was quenched by incubating in 3% hydrogen peroxide 
in methanol for 30 min, then blocked with rabbit serum 
(Dako #N1699), 30 min. The sections were incubated 
with polyclonal Rh anti-Toxoplasma antibody, diluted 
1:500 for 90 min and developed with DAB-Chromogen 
(Dako Carpenteria, CA) for about 5 min until signal de-
veloped and subsequently counterstained with hematox-
ylin then ammonia treated and dehydrated stepwise 
through alcohol, clear with xylene.  
2.6. Behavioral Test: Assessment of Pain Related 
Mechanical Allodynia by Testing Abdominal 
Withdrawal Threshold 
Abdominal withdrawal responses to mechanical stimuli 
Diclazuril Protects against Maternal Gastrointestinal Syndrome and Congenital Toxoplasmosis 
OPEN ACCESS                                                                                        IJCM 
96 
were quantified with von Frey monofilaments (Semmes- 
Weinstein Anesthesiometer Kit) according to our pre-
vious publications with some modification [11,21]. Bri- 
efly, mice were placed into plastic enclosures on the 
custom made screen meshed platform. The monofilament 
range used for this study included 5 different intensities 
corresponding to (hair diameter) gram force [(4.08) 1.0 g; 
(3.61) 0.4 g; (3.22) 0.166 g; (2.83) 0.07; (2.36) 0.02 g 
forces]. Testing for mechanical stimulation was per-
formed on the first and the last days of treatment. A sin-
gle trial consisted of 5 applications of the each filament 
used once every 6 seconds to allow the dam to cease any 
response and return to an inactive position. Mean values 
of the percentage of responses of the abdominal with-
drawal to each filament (mean withdrawal/5 × 100) were 
used as % scores in this study. This behavioral test re-
flected basal level for reflex score and any possible sen-
sory changes observed in the treated mice. Total 4 dams 
were tested per each group.  
2.7. Statistical Analysis 
Results are expressed as mean ± SEM unless otherwise 
stated. Data was evaluated with ANOVA followed by 
appropriate post hoc test (Tukey compared all pairs) us-
ing GraphPad Instat version 3 for Windows (GraphPad 
Software, San Diego, CA). Statistical significance was 
set at p < 0.05.  
3. Results  
3.1. Drug Safety and Tolerance  
In the initial study, naïve dams were provided diets con-
taining two different doses of low (65 mg/kg) and high 
(120 mg/kg) diclazuril or sham treatment. All dams vo-
luntarily consumed their diets with no adverse effect of 
clinical symptoms, changes in body weight gain rates or 
appearance detected in diclazuril treated dams compared 
to those receiving the sham treatment.  
3.2. Diclazuril Dose Related Efficacy and  
Toxoplasmosis in Model  
We compared efficacy of low and high doses of diclazu-
ril in dams infected with 0 or 100 tachyzoites during the 
2nd trimester pregnancy. Infected dams demonstrated 
moderate complications related to toxoplasmosis. As 
expected sham treatment provided no protective changes 
on the severity of the disease; while, dams treated with 
high dose diclazuril were significantly more protected 
against Toxoplasma infection and clinical symptoms 
compared to those receiving the low dose of diclazuril 
treatments (data not shown). Therefore, we selected the 
high dose (120 mg/kg) diclazuril for the following inves-
tigations.  
3.3. Efficacy of Diclazuril against Severity  
of Toxoplasmosis  
In the next study, we compared efficacy of high dose 
diclazuril (120 mg/kg) in dams infected with different 
quantity of single inoculum (0, 100, 300, 600) tachy-
zoites. Infected dams developed moderate to severe tox-
oplasmosis complications in tachyzoites dose dependent 
manner. Dams infected with high dose tachyzoites exhi-
bited significant increases in body weight mainly due to 
edema (p < 0.01) (Table 1). Additionally, these dams 
became anemic (Controls 44.5 ± 1.2 versus infected- 
dams 37 ± 2 p < 0.05) and developed hydrothorax and 
ascities. Diclazuril treatment effectively protected dams 
from anemia (41.1 ± 2.4), and excess pathological weight 
gain as a result of ascities (Table 1).  
3.4. Splenic Pathology  
Infected dams demonstrated splenomegaly in tachyzoites 
dose related manner (2 - 3 fold of normal control values), 
with massive infiltration of epithelioid cells and loss of 
germinal structure with significant increases in weight 
and length of splenic tissues compared with significant 
protection in infected but diclazuril treated dams 
(Figures 1(a) and (b)).  
3.5. Hepatic Pathology  
Hepatic tissue became pale in appearance and increased 
in weight due to infection and inflammatory response. 
Infected dams illustrated a mild to severe hepatitis [pa- 
thology score on scale 0 - 4 most severe lesions: 2.3 ± 
0.4 (100), 2.8 ± 0.3 (300), and 3.5 ± 0.01 (600 tachy-
zoites)] with distorted hepatic architecture, dysplastic 
hepatocytes formation, and multinucleated giant cells  
 
Table 1. Efficacy of diclazuril on infected dams in fetoma- 
ternal toxoplasmosis model. 
Tissues Control Infected Infected + treated 
Excess body  
weight (%) 0 62 ± 1
a 41 ± 2.5a 
Hematocrit (%) 44.5 ± 1.2 37 ± 1.4a 41.1 ± 2.4 
Hepatic weight (g) 1.78 ± 0.25b 3.4 ± 0.14b,a 3.18 ± 0.99a 
Colonic length (mm) 125 ± 2.5 87 ± 2.2a 99 ± 4a 
Heart weight (mg) 202 ± 10 315 ± 30a 247 ± 18a 
Uterus weight (g) 11.60 ± 0.5a 13.9 ± 0.7a 11.9 ± 1.9 
Hypersensitivity (%) 20 ± 0.5b 43 ± 2.5 40 ± 0.4 
Tissues from normal control dams (Control), those infected with 600 ta-
chyzoites from PTG strain, treated with sham (infected), and those Diclazu-
ril treated dams (Infected + treated). Animals were monitored daily X3/ 
until Day 16 of pregnancy before termination. Abdominal hypersensitivity 
to von Fray stimuli increased significantly in infected animals. p value b < 
0.01; a < 0.05. 
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Figure 1. Splenic length (a) and weight (b) increased due to inflammatory response in infected dams in tachyzoites dose de-
pendent manner and diclazuril significantly protected dams from pathogenesis. (a) = Splenic length from Control (Co) or 
infected with 300 tachyzoites (300 Tox)-diclazuril treated vs infected dams p < 0.01; Control vs infected with 600 tachyzoites 
(600 Tox) p < 0.001 (n = 6/group). 
 
transformation. In addition, moderate to diffused influx 
of inflammatory cells, including polymorphonuclear, mo- 
nonuclear and plasma cells, depicted in parenchyma with 
hepatocytes degeneration and necrosis in tachyzoites 
dose depended manner. Scattered tachyzoites in paren-
chyma were confirmed with Giemsa staining. Diclazuril 
treatment significantly protected dams from hepatic in-
jury also in tachyzoites dose related manner (100, 300, 
600) and accordingly ameliorated the hepatic pathology 
(infected-diclazuril treated versus infected sham treated p 
< 0.001, p < 0.01 and p < 0.05, Figure 2).  
3.6. Cardiac Pathology 
Dams exhibited mild to moderate myocarditis with infil-
tration of inflammatory cells into cardiomyocyte tissue, 
embedding scattered pseudocysts and tachyzoites (Table 
1). This was consistent with the detection of no pseudo-
cysts in the cardiac tissues from diclazuril treated ani-
mals. The presence of the scattered tachyzoites or pseu-
docysts was confirmed with, Giemsa and IHC staining of 
the tissue sections (not shown). Diclazuril treated dams 
were all protected and did not develop any detectable 
Toxoplasma organisms.  
3.7. Fetal Numbers, Weight and Length  
Most importantly, the fetal weight and length and the 
number of fetuses were significantly affected in infected 
dams with high dose tachyzoites (600 tachyzoites) lead-
ing to fetal retardation and/or fetal loss. In contrast the 
number of fetuses was protected in infected and diclazu-
ril treated dams and the fetal length and fetal weights 
were significantly improved (Figure 3). 
3.8. Pain Related Abdominal Response to Stimuli 
and Diclazuril Therapy  
Infected dams (600 tachyzoites) showed a significant 
pain related abdominal hypersensitivity (p < 0.01) to von 
Fray mechanical stimuli as demonstrated with abdominal 
spasm and withdrawal compared to the uninfected con-
trols. However, diclazuril treatment had no significant 
improvement on the abdominal hypersensitivity in in-
fected dams as compared to infected and sham treated 
animals (Table 1). 
4. Discussion 
Numerous reports indicate the clinical importance of 
toxoplasmosis complications and the need for a safe and 
effective therapeutic specifically for chronic infection 
and congenital toxoplasmosis [22]. The objectives of this 
investigation were to evaluate the efficacy of diclazuril 
against the progression of the gastrointestinal syndrome 
and maternal fetal toxoplasmosis in our murine model.  
Toxoplasma, a Category B classification by CDC and 
NIH, is a common parasite of animals, and causes severe 
foodborne diseases and in fetal, neonate and immuno-
compromised (AIDS/HIV) patients. Congenital trans-
mission of toxoplasmosis may result in serious complica-
tions including fetal death or lifelong adverse conse-
quences [1,23,24]. 
Present therapies for toxoplasmosis include pyrime-
thamine, sulfasalazine, sulfadiazine and spiramycin, 
which these therapies are not always effective and/or 
have a major side effects. Pyrimethamine is a pregnancy 
category C drug and can cause severe side effects in-
cluding bone marrow suppression in both mother as well  
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Figure 2. Slides from hepatic sections stained with H &E 
and scored from 0 normal control (Co) to 4 (most severe 
lesions) for pathological findings from infected dams com-
pared with those treated with diclazuril. Hepatic pathology 
scores increased in tachyzoites (Tox) dose dependent man-




Figure 3. Fetal weight from control (Co) dams, infected 
with tachyzoites (Tox) compared with those treated with 
diclazuril. 
 
as infant. In addition, more than half (58%) patients who 
receive spiramycin retain Toxoplasma DNA in their pe-
ripheral blood [9]. Although, a case of fetal bradycardia 
has been claimed to be associated with spiramycin ther-
apy [10] in general, spiramcyin is well tolerated and is 
more of preventive in early pregnancy but not efficacious 
when parasite has already passed the placenta. 
In a 20 year prospective clinical trial (1985-2005) of 
infected mothers (666/676) who were treated with spi-
ramycin alone or combined with pyrimethamine-sulfa- 
doxine with live born children, 112 (17%) confirmed 
with congenital toxoplasmosis and, 26% later developed 
chorioretinitis [8]. Similarly, in another study in France, 
from 257 live births from women with prenatal positive 
diagnosis for the toxoplasmosis were treated with both 
spiramycin and pyrimethamine-sulfadoxine, 66 (24%) 
children were infected, yielding transmission rates of 
toxoplasmosis of 7% in the first, 24% in the second, and 
59% in the third trimesters, respectively [25].  
Given these circumstances, there is a great need for 
more effective therapeutic modalities with less toxicity 
and better tolerated regimens for fetal and congenital 
toxoplasmosis as well as for the recurrent Toxoplasma 
related disease. 
In this report we have demonstrated that diclazuril 
treatment significantly reduces pathogenesis in maternal 
and fetal infection with toxoplasmosis during pregnancy. 
This is the first report demonstrating diclazuril to be safe 
and effective in pregnant dams as well as their nested 
fetuses and in higher doses than currently used in pre-
vention of coccidiosis.  
Diclazuril is mainly used in poultry industry to protect 
against coccidal infection and to treat clinical cases of 
EPM infection in horses caused by Apicomplexan pro-
tozoa S. neurona that is closely related to Toxoplasma 
[12,26-28]. Previously, diclazuril in lower dose (10 
mg/kg) was shown to be effective against experimental 
Toxoplasma infection in male mice [29] and an infected 
Hawaiian (Alala) bird [30].  
Diclazuril [4-chlorophenyl [2,6-dichloro-4-(4,5-dihy- 
dro-3H-3,5-dioxo-1,2,4-triazin-2-yl)pheny l acetonitrile], 
is a benzeneacetonitrile compound [26,27]. Following 
oral administration, it is rapidly absorbed to achieve 
steady-state concentration in plasma and cerebrospinal 
fluid (CSF) with peak concentrations occurring at 8 - 24 
h after single dose, sufficient to interfere with S. neurona 
proliferation with 95% inhibition rate [26,27].  
A major therapeutic advantage for dicalzuril is its 
highly specific anti-Apicomplexan effect because Api-
complexan agents, including Toxoplasma, are unusual 
among protozoa in that they contain protochlorophyllidae 
with traces of chlorophyll bound to the photosynthetic 
reaction centers [14]. The diclazuril/herbicide-binding 
region is shown to be highly conserved in Apicomplex-
ans, which results in a unique sensitivity of Apicom-
plexans to the herbicide related drug, diclazuril and asso-
ciated benzene acetonitriles. Therefore, diclazuril binds 
the chloroplast epitope and interacts with the D1 protein 
of the photosynthetic reaction center of Toxoplasma or-
ganelles without damaging the mammalian host cells. 
The fact that mammalian systems lack the protochloro-
phyllidae related diclazuril/herbicide binding region re-
sults in a very high therapeutic index for diclazuril and 
related agents. In addition, diclazuril is shown to down-
regulate expression of serine/threonine protein phospha-
tase (EtRACK) in second-generation merozoite of Eime-
ria tenella to induce apoptosis [31]. EtRACK has about 
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98% homology with Toxoplasma that demonstrates a 
possible mechanism of action for diclazuril. Recently, we 
reported efficacy of atovaquone (hydroxy-1,4-naphtho- 
quinone) against some aspects of gastrointestinal com-
plications in congenital toxoplasmosis [11]. However, 
diclazuril reveals better efficacy against anemia, colonic 
length improvement, hepatic complications and excess 
body weight. On the other hand, atovaquone was more 
effective in reducing pain related abdominal response to 
mechanical stimuli [11]. Therefore, diclazuril treatment 
protected dams against mild to moderate gastrointestinal 
syndrome and their fetuses from Toxoplasma infection. 
5. Conclusion 
This is the first report describing of diclazuril safety in 
pregnancy and efficacy against mild to moderate hepato- 
gastrointestinal complication and congenital toxoplasmo-
sis for which no satisfactory therapy is currently availa-
ble. As such, these findings warrant further investigations 
of this novel prophylactic and therapeutic approach to 
gastrointestinal as well as congenital toxoplasmosis.  
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Abbreviation 
BSA: Bovine serum albumin  
CDC: Center for Disease Control 
CNS; Central nervous system  
EPM: Equine Protozoal Myeloencephalitis 
FDA: Food and Drug administration 
H & E: Hematoxylin Eosin 
IACUC: Institutional Animal Care Use Committee 
IBC: Institutional Biosaftey Committee 
IHC: Immunohistochemical staining;  
i.p: Intraperitoneally 
MEM: Minimum essential medium 
PBS: phosphate buffer saline 
S. neurona: Sarcocystis neurona 
